These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Imaging of human tumor xenografts with an indium-111-labeled anti-epidermal growth factor receptor monoclonal antibody. Goldenberg A; Masui H; Divgi C; Kamrath H; Pentlow K; Mendelsohn J J Natl Cancer Inst; 1989 Nov; 81(21):1616-25. PubMed ID: 2795690 [TBL] [Abstract][Full Text] [Related]
11. Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts. Safavy A; Khazaeli MB; Safavy K; Mayo MS; Buchsbaum DJ Clin Cancer Res; 1999 Oct; 5(10 Suppl):2994s-3000s. PubMed ID: 10541333 [TBL] [Abstract][Full Text] [Related]
12. Radioimmunoscintigraphy of intracranial glioma xenograft with a technetium-99m-labeled mouse monoclonal antibody specifically recognizing type III mutant epidermal growth factor receptor. Takasu S; Takahashi T; Okamoto S; Oriuchi N; Nakayashiki N; Okamoto K; Muramatsu H; Hayashi T; Nakahara N; Mizuno M; Wakabayashi T; Higuchi T; Endo K; Kozaki K; Miyaishi O; Saga S; Ueda R; Yoshida J; Yoshikawa K J Neurooncol; 2003 Jul; 63(3):247-56. PubMed ID: 12892230 [TBL] [Abstract][Full Text] [Related]
13. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor. Crombet T; Torres O; Neninger E; Catalá M; Rodríguez N; Ramos M; Fernández E; Iznaga N; Pérez R; Lage A Cancer Biother Radiopharm; 2001 Feb; 16(1):93-102. PubMed ID: 11279803 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody. Kobayashi H; Wu C; Kim MK; Paik CH; Carrasquillo JA; Brechbiel MW Bioconjug Chem; 1999; 10(1):103-11. PubMed ID: 9893971 [TBL] [Abstract][Full Text] [Related]
15. A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer. Reilly RM; Kiarash R; Sandhu J; Lee YW; Cameron RG; Hendler A; Vallis K; Gariépy J J Nucl Med; 2000 May; 41(5):903-11. PubMed ID: 10809207 [TBL] [Abstract][Full Text] [Related]
16. Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin. Torres LA; Perera A; Batista JF; Hernández A; Crombet T; Ramos M; Neninger E; Pérez M; Sánchez EL; Romero S; Aguilar V; Coca MA; Iznaga-Escobar N Nucl Med Commun; 2005 Dec; 26(12):1049-57. PubMed ID: 16264350 [TBL] [Abstract][Full Text] [Related]
17. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. Johns TG; Stockert E; Ritter G; Jungbluth AA; Huang HJ; Cavenee WK; Smyth FE; Hall CM; Watson N; Nice EC; Gullick WJ; Old LJ; Burgess AW; Scott AM Int J Cancer; 2002 Mar; 98(3):398-408. PubMed ID: 11920591 [TBL] [Abstract][Full Text] [Related]
18. Superior localisation and imaging of radiolabelled monoclonal antibody E48 F(ab')2 fragment in xenografts of human squamous cell carcinoma of the head and neck and of the vulva as compared to monoclonal antibody E48 IgG. Gerretsen M; Quak JJ; Suh JS; van Walsum M; Meijer CJ; Snow GB; van Dongen GA Br J Cancer; 1991 Jan; 63(1):37-44. PubMed ID: 1989663 [TBL] [Abstract][Full Text] [Related]